EA201290372A1 - Композиция с замедленным высвобождением - Google Patents

Композиция с замедленным высвобождением

Info

Publication number
EA201290372A1
EA201290372A1 EA201290372A EA201290372A EA201290372A1 EA 201290372 A1 EA201290372 A1 EA 201290372A1 EA 201290372 A EA201290372 A EA 201290372A EA 201290372 A EA201290372 A EA 201290372A EA 201290372 A1 EA201290372 A1 EA 201290372A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
salt
extended period
time
present
Prior art date
Application number
EA201290372A
Other languages
English (en)
Other versions
EA020865B1 (ru
Inventor
Томомити Футо
Хикару Таира
Сейтаро Мидзуками
Наоюки Мурата
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201290372A1 publication Critical patent/EA201290372A1/ru
Publication of EA020865B1 publication Critical patent/EA020865B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к композиции с замедленным высвобождением, включающей в себя производное метастина и сополимер молочной кислоты - гликолевой кислоты, имеющий среднемассовую молекулярную массу приблизительно от 5000 до 40000, или его соль. Композиция с замедленным высвобождением по настоящему изобретению медленно и стабильно высвобождает соединение (I) или его соль в течение продолжительного периода времени и демонстрирует медицинский эффект соединения (I) или его соли в течение продолжительного периода времени. Помимо этого, композиция с замедленным высвобождением по настоящему изобретению, которая улучшает соблюдение пациентом режима и схемы лечения, благодаря уменьшению количества введений, представляет собой отличную композицию в качестве клинического лекарственного средства.
EA201290372A 2009-12-22 2010-12-21 Композиция с замедленным высвобождением EA020865B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009290364 2009-12-22
JP2010144793 2010-06-25
PCT/JP2010/073665 WO2011078394A2 (en) 2009-12-22 2010-12-21 Sustained-release formulation

Publications (2)

Publication Number Publication Date
EA201290372A1 true EA201290372A1 (ru) 2012-12-28
EA020865B1 EA020865B1 (ru) 2015-02-27

Family

ID=43743497

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290372A EA020865B1 (ru) 2009-12-22 2010-12-21 Композиция с замедленным высвобождением

Country Status (26)

Country Link
US (2) US20120302508A1 (ru)
EP (1) EP2515878B1 (ru)
JP (3) JP2013514968A (ru)
KR (1) KR20120098906A (ru)
CN (2) CN102665690A (ru)
AR (1) AR079657A1 (ru)
AU (1) AU2010336168A1 (ru)
BR (1) BR112012014947A2 (ru)
CA (1) CA2785021C (ru)
CO (1) CO6551752A2 (ru)
CR (1) CR20120290A (ru)
DO (1) DOP2012000171A (ru)
EA (1) EA020865B1 (ru)
EC (1) ECSP12011992A (ru)
ES (1) ES2434315T3 (ru)
IL (1) IL219967A0 (ru)
MA (1) MA33910B1 (ru)
MX (1) MX2012006441A (ru)
NZ (1) NZ600157A (ru)
PE (1) PE20121481A1 (ru)
SG (1) SG181436A1 (ru)
TN (1) TN2012000255A1 (ru)
TW (1) TW201125575A (ru)
UY (1) UY33127A (ru)
WO (1) WO2011078394A2 (ru)
ZA (1) ZA201203775B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
IL311335A (en) 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
EP1317304B1 (en) * 2000-09-01 2011-04-27 Palmaya Pty Ltd. Slow release pharmaceutical preparation and method of administering same
WO2002043709A1 (fr) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
KR20050090420A (ko) * 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
SG153865A1 (en) 2004-06-25 2009-07-29 Takeda Pharmaceutical Metastin derivatives and use thereof
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN1923284A (zh) * 2005-08-30 2007-03-07 孔庆忠 抗癌药物缓释注射剂及其应用
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
KR101522035B1 (ko) * 2006-12-18 2015-05-20 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물 및 이의 제조 방법
JPWO2009131191A1 (ja) * 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
PE20110939A1 (es) * 2008-12-29 2012-01-19 Takeda Pharmaceutical Agente preventivo/terapeutico contra el cancer
RU2582678C2 (ru) * 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы

Also Published As

Publication number Publication date
NZ600157A (en) 2013-07-26
WO2011078394A3 (en) 2012-03-15
BR112012014947A2 (pt) 2019-09-24
ECSP12011992A (es) 2012-07-31
ZA201203775B (en) 2013-08-28
MA33910B1 (fr) 2013-01-02
JP6472730B2 (ja) 2019-02-20
AU2010336168A1 (en) 2012-06-14
IL219967A0 (en) 2012-07-31
SG181436A1 (en) 2012-07-30
DOP2012000171A (es) 2012-08-31
UY33127A (es) 2011-07-29
JP2013514968A (ja) 2013-05-02
US20120302508A1 (en) 2012-11-29
PE20121481A1 (es) 2012-11-12
EP2515878A2 (en) 2012-10-31
WO2011078394A2 (en) 2011-06-30
AR079657A1 (es) 2012-02-08
CR20120290A (es) 2012-09-06
CA2785021C (en) 2019-03-05
JP2016029045A (ja) 2016-03-03
EP2515878B1 (en) 2013-10-30
CN107412725A (zh) 2017-12-01
CO6551752A2 (es) 2012-10-31
ES2434315T3 (es) 2013-12-16
CN102665690A (zh) 2012-09-12
TW201125575A (en) 2011-08-01
KR20120098906A (ko) 2012-09-05
JP2017160201A (ja) 2017-09-14
CA2785021A1 (en) 2011-06-30
US20180228732A1 (en) 2018-08-16
TN2012000255A1 (en) 2013-12-12
EA020865B1 (ru) 2015-02-27
MX2012006441A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
EA201200318A1 (ru) Гетероциклические оксимы
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
MX348653B (es) Derivados ester de acido boronico ciclico y sus usos terapeuticos.
MX2013007537A (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
GEP201706656B (en) 2-thiopyrimidinones
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
MX2020005736A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
IL212596A (en) Its octanidine or its pharmaceutical salt is combined in a solution with polyalcohol
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
EA201290372A1 (ru) Композиция с замедленным высвобождением
NZ609596A (en) Cyclohexane derivative compound
EA201291303A1 (ru) Композиция с замедленным высвобождением
JP2011504736A5 (ru)
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
EA201391314A1 (ru) Новое фенилпиридиновое производное и содержащее его лекарственное средство
NZ592378A (en) Choline and tromethamine salt of licofelone
RU2014128528A (ru) Лечение диабета I и II типа
TH118942A (th) สูตรผสมที่ปลดปล่อยเป็นเวลานาน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU